Manus Neorodynamica

The patented NeuroMotor Pen™ offers clinicians an accurate and objective assessment of movement abnormalities for diagnostic and prognostic purposes in a convenient, noninvasive way. Around 145,000 people live with Parkinson’s disease in the UK, and it’s said to be the fastest-growing neurological condition in the world, so the work of Manus Neurodynamica carries significant impact potential.

It employs sensors linked with software that analyse the slightest limb and hand movements to help doctors assess whether a patient has early signs of conditions like Parkinson’s. In addition to providing a quick, inexpensive, non invasive, and objective aid to diagnosis, the CE-marked product also helps with the ongoing monitoring of those conditions.

With the potential to radically improve the efficiency of patient diagnosis and monitoring - leading to more streamlined pathways, reduced costs and improved patient experience and quality of life - SIS Ventures was delighted to invest over £100,000 in a £1.2 million funding round at the end of 2020.

With the potential to radically improve the efficiency of patient diagnosis and monitoring - leading to more streamlined pathways, reduced costs and improved patient experience and quality of life - SIS Ventures was delighted to invest over £100,000 in a £1.2 million funding round at the end of 2020.

The Edinburgh-based MedTech company is now rolling out its NeuroMotor Pen™ in the UKand Benelux markets, while also progressing work to secure regulatory approval to start selling in the US.

The pen has passed clinical trials with the NHS in the North-East of England and Scotland and is currently being used by Northumbria NHS Foundation Trust.